Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... , May 22, 2015 ... by Product (1D & 2D Gel Electrophoresis, Agarose & ... MEKC, Reagents, Informatics), by Application & by End User ... Electrophoresis Market is expected to reach around $1.98 Billion ... forecast period 2015 to 2020. Browse ...
    (Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
    (Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
    (Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
    Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
    ... Fisher,Scientific Inc. (NYSE: TMO ) today ... a leading third-party logistics provider to the,pharmaceutical ... was previously majority-owned by Arsenal Capital,Partners. With ... Priority,Solutions offers a comprehensive range of services ...
    ... With a special eye for the,details hidden from casual ... G. Aspinall. Photographs of architectural details from beaches,to buildings ... fore. The,collection includes images from seven different countries., ... the,president of Genzyme Genetics, is also a talented artist ...
    ... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... Chief,Executive Officer, is scheduled to present at the ... EDT on Wednesday, October 10. The presentation ... be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ,657575 ...
    Cached Biology Technology:Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 3Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 4An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery 2
    (Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
    (Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
    (Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
    Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
    ... group of leading UK scientists and social scientists led by the ... joined-up thinking on the emerging politics of plants. Green is ... of plants from food to fuel, industrial feedstocks to carbon ... cornerstone of the global economy. But such fame comes ...
    ... Feb. 24 BIO-key International, Inc. (OTC Bulletin Board: ... biometric identification solutions, today reported results for the fourth ... Company,s results reflected profitability for the fourth quarter and ... strong revenue growth for the quarter and the year. ...
    ... Damon Runyon Cancer Research Foundation named 13 new ... Award Committee review. The recipients of this ... basic and translational cancer research in the laboratories ... The Fellowship is specifically intended to encourage the ...
    Cached Biology News:Plants are political hot potatoes 2BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 2BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 3BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 4BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 5BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 6Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 4